Liquidia is a biopharmaceutical company that sells YUTREPIA, an inhaled treprostinil treatment for pulmonary arterial hypertension. It last closed at $54.43 on Nov 20, down 3.88% on the day. The next earnings report for LQDA is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, LQDA reported EPS of -$2.64 on revenue of $225.3M, with revenue up 314.6% from a year ago. Over its last 8 reports the stock moved an average of 7.9% the session after earnings. Over the last 12 months LQDA insiders bought $318K of stock on the open market and sold $226.9M, according to SEC Form 4 filings.
AI Auto Pilots
Is LQDA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LQDA.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on LQDAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
LQDA · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend
The stock is 9% above its 20 day and 12% above its 50 day average. It is 1% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 59). The nearest support is the Pivot S1 at $53.20, and the nearest resistance the 200 day average at $55.02.
Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityHigh, 6.6%/day
Key levels
$93.6152 week high+72.0%
$62.72100 day average+15.2%
$59.50Swing high (Nov 13)+9.3%
$56.44Pivot R1+3.7%
$55.20Pivot+1.4%
$55.02200 day average+1.1%
$54.43Last close
$53.20Pivot S1−2.3%
$53.06Swing low (Jun 3)−2.5%
$49.7920 day average−8.5%
$47.7750 day average−12.2%
$22.3152 week low−59.0%
Indicators
RSI (14)
59.40
Middle of its range
Neutral
MACD
3.31
Above its signal line
Bullish
Stochastic
79.5
Middle of its range
Neutral
ADX (14)
32.5
Trending up
Williams %R
-28.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
68.3
Oversold below −100, overbought above 100
Neutral
Rate of change
+22.6%
Change over 10 sessions
Bullish
ATR (14)
$3.61
Typical daily range, 6.6% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 18.7%/day
Key levels
$93.6152 week high+72.0%
$62.72100 day average+15.2%
$59.50Swing high (Nov 13)+9.3%
$56.44Pivot R1+3.7%
$55.20Pivot+1.4%
$55.02200 day average+1.1%
$54.43Last close
$53.20Pivot S1−2.3%
$53.06Swing low (Jun 3)−2.5%
$49.7920 day average−8.5%
$47.7750 day average−12.2%
$22.3152 week low−59.0%
Indicators
RSI (14)
49.81
Middle of its range
Neutral
MACD
-2.78
Below its signal line
Bearish
Stochastic
46.0
Middle of its range
Neutral
ADX (14)
25.0
Trending down
Williams %R
-42.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-28.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−18.4%
Change over 10 sessions
Bearish
ATR (14)
$10.19
Typical daily range, 18.7% of price
MA 10Above
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for LQDA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how LQDA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow LQDA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for LQDAHow many large options trades hit LQDA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in LQDA in the last 90 days.
From SEC Form 4 filings by LQDA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LQDA is in one of them and how their past LQDA trades turned out.
Liquidia is a biopharmaceutical company based in Morrisville, North Carolina, that develops and sells medicines for lung and blood vessel diseases. Its main product is YUTREPIA, an inhaled treprostinil powder used to treat pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease. The company also shares profits from a generic treprostinil injection sold in the United States and is developing other treatments, including for pulmonary hypertension linked to COPD. Its customers include healthcare providers who treat these patients and the organizations that distribute and pay for these medicines.